STADA: Dr. Matthias Wiedenfels to become Chief Corporate Development and Central Services Officer – STADA's Executive Board expanded to four with additional specialist expertise
05/03/2013 . Ad hoc Release
Ad hoc release according to § 15 WpHG
Bad Vilbel, May 3, 2013 – In accordance with a contract signed today, Dr. Matthias Wiedenfels (40) is to become Chief Corporate Development & Central Services Officer which includes the areas Human Resources, Legal, IP/Patents, Compliance, Risk Management and Export Control at STADA Arzneimittel AG. Dr. Wiedenfels will take up his Executive Board duties today. The Supervisory Board has appointed him as Executive Board member until December 31, 2016.
Dr. Wiedenfels studied law and from 2002 initially worked as a lawyer in an international corporate law firm. At STADA, Dr. Wiedenfels initially assumed the position as Head of the Legal Department and General Counsel from 2009 and already just a short time after that also assumed responsibility for the Patent and Human Resources departments. In 2010, Dr. Wiedenfels also became Chief Compliance Officer. Since 2011, his responsibilities have also included Group Risk Management. In addition, Dr. Wiedenfels has also held various management positions at individual local subsidiaries. Most recently, Dr. Wiedenfels played already a part in all important Group decisions as Senior Vice President.
With the appointment of Dr. Wiedenfels, STADA's Executive Board expands to four members. This is a reflection of the increased size of the company and the corresponding increase in the number of tasks for the individual members of the Executive Board.
The Executive Board of STADA Arzneimittel AG thus now consists of Hartmut Retzlaff, Chairman of the Executive Board, Helmut Kraft, Chief Financial Officer, Dr. Axel Müller, Chief Production & Development Officer as well as Dr. Matthias Wiedenfels, Chief Corporate Development & Central Services Officer.
The Executive Board contract of Dr. Wiedenfels is based – as are the contracts of the other three members of the Executive Board – on a standardized compensation structure in line with the new legal requirements from the Law for the Appropriateness of Executive Board Remuneration (VorstAG) that has been approved by STADA’s Annual General Meeting 2011.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506